Can COVID vaccines stop transmission? Scientists race to find answers15 Mar, 2021
As countries roll out vaccines that prevent COVID-19, studies are under way to determine whether shots can also stop people from getting infected and passing on the SARS-CoV-2 virus. Vaccines that prevent transmission could help to bring the pandemic under control if they are given to enough people.
Preliminary analyses suggest that at least some vaccines are likely to have a transmission-blocking effect. But confirming that effect — and how strong it will be — is tricky because a drop in infections in a given region might be explained by other factors, such as lockdowns and behaviour changes. Not only that, the virus can spread from asymptomatic carriers, which makes it hard to detect those infections.
“These are among the hardest types of studies to do,” says Marc Lipsitch, an infectious-disease epidemiologist at the Harvard T. H. Chan School of Public Health in Boston, Massachusetts. “All of us are out there, hungrily trying to see what we can get out of little bits of data that do come out,” he says. Results from some studies are expected in the next few weeks.
Although most clinical trials of COVID-19 vaccines showed that vaccines prevented the disease, some trial results also offered clues that shots might prevent infection. A vaccine that is highly effective at preventing people from acquiring the infection in the first place would help to reduce transmission, says Larry Corey, a vaccinologist at the Fred Hutchinson Cancer Research Center in Seattle, Washington.
During the trial of Moderna's vaccine, produced in Boston, researchers swabbed all participants to see if they had any viral RNA. They saw a two-thirds drop in the number of asymptomatic infections among people who received the first shot of the two-dose vaccine, compared with those who received a placebo. But they tested people only twice, about a month apart, so might have missed infections.
The UK trial of the vaccine produced by the University of Oxford and AstraZeneca swabbed participants every week, and estimated a 49.3% reduction in asymptomatic infections among a subset of vaccinated participants compared with the unvaccinated group.
Pfizer, based in New York City and maker of another leading COVID-19 vaccine, says that it will start swabbing participants every two weeks in vaccine trials taking place in the United States and Argentina, to see whether the shot can prevent infection.
For reading full text click the link.